Advertisement
U.S. markets closed

Genprex, Inc. (GNPX)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.6800-0.1000 (-3.60%)
At close: 04:00PM EDT
2.7400 +0.06 (+2.24%)
After hours: 05:17PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close2.7800
Open2.7501
Bid2.6200 x 100
Ask2.7900 x 100
Day's Range2.6500 - 2.8699
52 Week Range2.5000 - 46.0000
Volume19,698
Avg. Volume87,211
Market Cap5.12M
Beta (5Y Monthly)-0.63
PE Ratio (TTM)N/A
EPS (TTM)-22.5600
Earnings DateMay 22, 2024 - May 26, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est165.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GNPX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Genprex, Inc.
    Analyst Report: Perrigo Company plcPerrigo is the leading provider of over-the-counter generic drugs with over 100 global locations. The company was formed in 1887 as a packager of home remedies and has grown with the migration of prescriptions switching to OTC and later with strategic acquisitions. The company has a portfolio of more than 3,000 product formulations and 14,000 stock-keeping units. Most of its manufacturing and customer base reside in North America. With the most recent management change, the company announced a narrower focus on consumer wellness in conjunction with the divestiture of animal health, acquisition of Ranir Global Holdings, and plans to sell or spin off the prescription business.
    Rating
    Fair Value
    Economic Moat
    3 years agoMorningstar
View more